APGOT-OV19: A Randomized, Multicenter, Open-Label Phase 3 Study to Evaluate the Efficacy of GSK5733584 Combined with Bevacizumab Versus Platinum doublet Combined with Bevacizumab in Patients with Platinum-Sensitive Ovarian Cancer.